Table III.
Microdeletion profiles among included patients.
| Microdeletion locus | All | T-ALL | B-ALL | P-value |
|---|---|---|---|---|
| IKZF1 | 28 (33.73) | 2 (10.52) | 26 (40.62) | 0.01468 |
| CDKN2A/B | 51 (61.44) | 13 (68.42) | 38 (59.37) | 0.65777 |
| MIR31 | 18 (23.07) | 3 (18.75) | 15 (24.19) | 0.75102 |
| PAX5 | 16 (20.00) | 2 (11.76) | 14 (22.22) | 0.50036 |
| PAR1 | 19 (26.76) | 3 (23.07) | 16 (27.58) | 1.00000 |
| ETV6 | 17 (24.28) | 0 (0) | 17 (29.82) | 0.02876 |
| BTG1 | 5 (7.14) | 0 (0) | 5 (8.77) | 0.57571 |
| EBF1 | 5 (7.14) | 0 (0) | 5 (8.77) | 0.57571 |
| RB1 | 10 (14.08) | 2 (15.38) | 8 (13.79) | 1.00000 |
Categorical variables were compared using the χ2 test. All data presented at the number of deletions with percentages in brackets. IKZF1, IKAROS family zinc finger 1; CDKN2A/B, cyclin dependent kinase inhibitor 2A/B; MIR31, microRNA 31; PAX5, paired box 5; PAR1, pseudoautosomal region 1; ETV6, ETS variant 6; BTG1, B-cell translocation gene 1 protein; EBF1, early B-cell factor 1; RB1, retinoblastoma 1.